miR-301a as an NF-κB activator in pancreatic cancer cells.
Journal: 2011/February - EMBO Journal
ISSN: 1460-2075
Abstract:
NF-κB is constitutively activated in most human pancreatic adenocarcinoma, which is a deadly malignancy with a 5-year survival rate of about 5%. In this work, we investigate whether microRNAs (miRNAs) contribute to NF-κB activation in pancreatic cancer. We demonstrate that miR-301a down-regulates NF-κB-repressing factor (Nkrf) and elevates NF-κB activation. As NF-κB promotes the transcription of miR-301a, our results support a positive feedback loop as a mechanism for persistent NF-κB activation, in which miR-301a represses Nkrf to elevate NF-κB activity, which in turn promotes miR-301a transcription. Nkrf was found down-regulated and miR-301a up-regulated in human pancreatic adenocarcinoma tissues. Moreover, miR-301a inhibition or Nkrf up-regulation in pancreatic cancer cells led to reduced NF-κB target gene expression and attenuated xenograft tumour growth, indicating that miR-301a overexpression contributes to NF-κB activation. Revealing this novel mechanism of NF-κB activation by an miRNA offers new avenues for therapeutic interventions against pancreatic cancer.
Relations:
Content
Citations
(88)
References
(45)
Diseases
(1)
Chemicals
(3)
Genes
(1)
Organisms
(4)
Processes
(3)
Anatomy
(3)
Affiliates
(1)
Similar articles
Articles by the same authors
Discussion board
EMBO J 30(1): 57-67

miR-301a as an NF-κB activator in pancreatic cancer cells

Supplementary Material

Supplementary Table S1:
Supplementary data:
Review Process File:
Department of Biochemistry and Molecular Biology, University of Louisville, Louisville, KY, USA
Department of Surgery, Division of Surgical Oncology, University of Louisville, Louisville, KY, USA
Department of Medicine, Division of Cardiovascular Medicine, University of Louisville, Louisville, KY, USA
Diabetes and Obesity Center, School of Medicine, University of Louisville, Louisville, KY, USA
Department of Pathology and Laboratory Medicine/Oncology, Paul P. Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
Department of Biochemistry and Molecular Biology, University of Louisville, 319 Abraham Flexner Way, Room 513/A-building, Louisville, KY 40202, USA. Tel.: +1 502 852 7551; Fax: +1 502 852 6222; E-mail: ude.ellivsiuol@il.gnoy
These authors contributed equally to this work
Received 2010 Jun 23; Accepted 2010 Oct 28.

Abstract

NF-κB is constitutively activated in most human pancreatic adenocarcinoma, which is a deadly malignancy with a 5-year survival rate of about 5%. In this work, we investigate whether microRNAs (miRNAs) contribute to NF-κB activation in pancreatic cancer. We demonstrate that miR-301a down-regulates NF-κB-repressing factor (Nkrf) and elevates NF-κB activation. As NF-κB promotes the transcription of miR-301a, our results support a positive feedback loop as a mechanism for persistent NF-κB activation, in which miR-301a represses Nkrf to elevate NF-κB activity, which in turn promotes miR-301a transcription. Nkrf was found down-regulated and miR-301a up-regulated in human pancreatic adenocarcinoma tissues. Moreover, miR-301a inhibition or Nkrf up-regulation in pancreatic cancer cells led to reduced NF-κB target gene expression and attenuated xenograft tumour growth, indicating that miR-301a overexpression contributes to NF-κB activation. Revealing this novel mechanism of NF-κB activation by an miRNA offers new avenues for therapeutic interventions against pancreatic cancer.

Keywords: microRNA, miR-301a, NF-κB, NF-κB-repressing factor, pancreatic cancer
Abstract
Click here to view.(211K, xls)Click here to view.(3.0M, pdf)Click here to view.(429K, pdf)

Acknowledgments

This project is supported by Clinical & Translational Science Pilot Grant Program Innovative Award and the Diabetes and Obesity Center at University of Louisville funded by NCRR/NIH (P20 RR024489). YL is also supported by the Center for Environmental Genomics and Integrated Biology at University of Louisville funded by NIEHS/NIH (P30 ES014443) and a Scientist Development Grant from American Heart Association. We are indebted to the critical reviews of Drs Nancy Martin and Robert Mitchell and Ms Juanita R Barker and to Cox2 promoter constructs from Drs Shozo Yamamoto and Tomoko Takano. YL is extremely grateful to Drs Aruni Bhatnagar and Kenneth S Ramos for their mentoring and support.

Acknowledgments

Footnotes

The authors declare that they have no conflict of interest.

Footnotes
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.